In 2011, Teiten et al. showed that it is effective in combating prostate cancer by blocking the Wnt/Catenin pathway in an androgen receptor-dependent manner while triggering cell cycle arrest during the G2 phase and autophagy [113]. This evidence concerns the gene AR and Familial prostate cancer.